# Arvinas, Inc.: overview

ARVN · Nasdaq · CIK 1655759 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/arvn.md) · [Financials](/companies/arvn/financials.md) · [Filings](/companies/arvn/filings.md) · [Insiders](/companies/arvn/insiders.md)

Latest reported revenue: [$249.7m](/filings/0001628280-26-052554.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 4, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-052554).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [102](/filings/0001628280-25-049527.md) | [59.2 d](/filings/0001628280-26-011226.md) | [189](/filings/0001628280-26-033669.md) | [22.4](/filings/0001628280-26-052554.md) | [41.9](/filings/0001628280-25-049527.md) | [9.5 d](/filings/0001628280-26-011226.md) | [15.6](/filings/0001628280-26-033669.md) | [250](/filings/0001628280-26-052554.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(58.9%)](/filings/0001628280-25-049527.md) | [(98.3%) d](/filings/0001628280-26-011226.md) | [37.8%](/filings/0001628280-26-033669.md) | [(319.2%)](/filings/0001628280-26-052554.md) | [(104.5%)](/filings/0001628280-25-049527.md) | [(785.3%) d](/filings/0001628280-26-011226.md) | [(409.0%)](/filings/0001628280-26-033669.md) | [65.7%](/filings/0001628280-26-052554.md) |
| Net margin | % | [(48.0%)](/filings/0001628280-25-049527.md) | [(76.2%) d](/filings/0001628280-26-011226.md) | [43.9%](/filings/0001628280-26-033669.md) | [(273.2%)](/filings/0001628280-26-052554.md) | [(83.8%)](/filings/0001628280-25-049527.md) | [(709.5%) d](/filings/0001628280-26-011226.md) | [(369.2%)](/filings/0001628280-26-033669.md) | [67.8%](/filings/0001628280-26-052554.md) |
| Diluted EPS | $ per share | [(0.68)](/filings/0001628280-25-049527.md) | not reported | [1.14](/filings/0001628280-26-033669.md) | [(0.84)](/filings/0001628280-26-052554.md) | [(0.48)](/filings/0001628280-25-049527.md) | not reported | [(0.90)](/filings/0001628280-26-033669.md) | [2.58](/filings/0001628280-26-052554.md) |
| Free cash flow | $m | [(129) d](/filings/0001628280-25-049527.md) | [(84.4) d](/filings/0001628280-26-011226.md) | [(89.3)](/filings/0001628280-26-033669.md) | [(96.6) d](/filings/0001628280-26-052554.md) | [(59.2) d](/filings/0001628280-25-049527.md) | [(30.6) d](/filings/0001628280-26-011226.md) | [(70.5)](/filings/0001628280-26-033669.md) | [(48.5) d](/filings/0001628280-26-052554.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [46.7](/filings/0001628280-22-004262.md) | [131](/filings/0001655759-25-000016.md) | [78.5](/filings/0001628280-26-011226.md) | [263](/filings/0001628280-26-011226.md) | [263](/filings/0001628280-26-011226.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(403.4%)](/filings/0001655759-24-000018.md) | [(200.3%)](/filings/0001655759-25-000016.md) | [(511.5%)](/filings/0001628280-26-011226.md) | [(95.0%)](/filings/0001628280-26-011226.md) | [(45.1%)](/filings/0001628280-26-011226.md) |
| Net margin | % | [(409.0%)](/filings/0001655759-24-000018.md) | [(215.0%)](/filings/0001655759-25-000016.md) | [(467.9%)](/filings/0001628280-26-011226.md) | [(75.5%)](/filings/0001628280-26-011226.md) | [(30.8%)](/filings/0001628280-26-011226.md) |
| Diluted EPS | $ per share | [(3.82)](/filings/0001655759-24-000018.md) | [(5.31)](/filings/0001655759-25-000016.md) | [(6.62)](/filings/0001628280-26-011226.md) | [(2.77)](/filings/0001628280-26-011226.md) | [(1.14)](/filings/0001628280-26-011226.md) |
| Free cash flow | $m | [555](/filings/0001655759-24-000018.md) | [(280)](/filings/0001655759-25-000016.md) | [(351)](/filings/0001628280-26-011226.md) | [(261)](/filings/0001628280-26-011226.md) | [(276)](/filings/0001628280-26-011226.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/arvn/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $63.2m | 7,609,123 |  | Added +811,539 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $34.3m | 4,123,399 |  | Added +233,771 |
| [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $29.0m | 3,495,153 |  | Reduced −143,414 |
| [Pfizer Inc](/funds/78003.md) | 2026-06-30 | $27.7m | 3,457,815 |  | Unchanged |
| [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $23.2m | 2,796,000 |  | Added +818,000 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $22.6m | 2,714,163 |  | Added +24,801 |
| [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $21.4m | 2,573,447 |  | Added +741,333 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $18.3m | 2,196,872 |  | Added +368,400 |
| [Nextech Invest Ltd.](/funds/1595430.md) | 2026-06-30 | $17.1m | 1,122,713 |  | Added +583,319 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $13.9m | 1,667,265 |  | Added +110,158 |

## Recent filings

[All 595 filings](/companies/arvn/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-04 | 16:08 ET | [10-Q](/filings/0001628280-26-052554.md) | Quarterly report, period 2026-06-30 | 0001628280-26-052554 |
| 2026-08-04 | 07:02 ET | [8-K](/filings/0001628280-26-052139.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-052139 |
| 2026-06-25 | 16:18 ET | [8-K](/filings/0001628280-26-045520.md) | 5.07 Shareholder vote results | 0001628280-26-045520 |
| 2026-06-22 | 16:10 ET | [8-K](/filings/0001628280-26-044627.md) | 5.02 Departure or appointment of officers or directors | 0001628280-26-044627 |
| 2026-06-16 | 16:30 ET | [8-K](/filings/0001628280-26-043559.md) | 8.01 Other events | 0001628280-26-043559 |
| 2026-06-02 | 16:39 ET | [8-K](/filings/0001628280-26-039818.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-039818 |
| 2026-05-12 | 07:15 ET | [8-K](/filings/0001628280-26-033875.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-033875 |
| 2026-05-12 | 07:14 ET | [8-K](/filings/0001628280-26-033874.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-033874 |
| 2026-05-11 | 17:18 ET | [10-Q](/filings/0001628280-26-033669.md) | Quarterly report, period 2026-03-31 | 0001628280-26-033669 |
| 2026-05-01 | 12:58 ET | [8-K](/filings/0001628280-26-029210.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-029210 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-011226.md), filed Feb 24, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/8f16911f-3b30-402a-9284-15233a32e519)

## About the filer

- CIK: 1655759
- Tickers: ARVN
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.